Medical uses Saccharomyces boulardii

1 medical uses

1.1 irritable bowel syndrome
1.2 inflammatory bowel disease
1.3 travelers diarrhea
1.4 antibiotic-associated diarrhea
1.5 clostridium difficile infection
1.6 hiv/aids-associated diarrhea
1.7 elimination of helicobacter pylori infection
1.8 blastocystosis
1.9 acute gastroenteritis

medical uses

numerous randomized, double-blind, placebo-controlled studies show efficacy of s. boulardii in treatment , prevention of gastrointestinal disorders.

irritable bowel syndrome

a prospective placebo-controlled study found patients diarrhea-predominant irritable bowel syndrome had significant reduction on number , consistency of bowel movements.

another study in 2011 did not find change in bowel frequency.

inflammatory bowel disease

further benefits inflammatory bowel disease patients have been suggested in prevention of relapse in crohn s disease patients in remission , benefits ulcerative colitis patients presenting moderate symptoms.

travelers diarrhea

austrian vacationers taking s. boulardii traveling around world found have fewer occurrences of travelers diarrhea taking placebo. meta-analysis of 12 studies 1977 2005 investigating efficacy of probiotics found them safe , effective treatment of travelers diarrhea, having pooled relative risk of 0.85 respect placebo (between 0.79 , 0.91 95% confidence). 3 of 4 studies concerning s. boulardii found effective treatment.

antibiotic-associated diarrhea

evidence exists use in preventative treatment of antibiotic-associated diarrhea (aad) in adults. further evidence indicates use prevent aad in children. potential efficacy of probiotic aad prevention dependent on probiotic strain(s) used , on dosage. 2015 cochrane review recommended lactobacillus rhamnosus or saccharomyces boulardii @ 5 40 billion colony forming units/day prevention of antibiotic-associated diarrhea in children given modest nnt , likelihood adverse events rare. recent meta-analysis of twenty-one randomised controlled trials (4780 participants) confirms s. boulardii effective in reducing risk of antibiotic-associated diarrhoea in children , adults.

clostridium difficile infection

saccharomyces boulardii showed reduction of relapses in specific patients recurrent clostridium difficile infection , may effective secondary prevention of clostridium difficile infection.

hiv/aids-associated diarrhea

s. boulardii has been shown increase recovery rate of stage iv aids patients suffering diarrhea versus placebo. on average, patients receiving s. boulardii gained weight, while placebo group lost weight on 18-month trial. no adverse reactions observed in these immunocompromised patients.

elimination of helicobacter pylori infection

the addition of s. boulardii standard triple medication protocol elimination of helicobacter pylori infection showed significant increase in eradication rates in meta-analysis, though eradication rates still not exceptional. supplement decreased usual side effects of h. pylori eradication therapy including diarrhea , nausea.

blastocystosis

also, evidence shows potential benefits of s. boulardii in treatment of blastocystosis.

acute gastroenteritis

a position paper published espghan working group probiotics , prebiotics based on systematic reviewes , randomized controlled trials (rcts) suggested saccharomyces boulardii (low quality of evidence, strong recommendation) may considered in management of children acute gastroenteritis in addition rehydration therapy.